Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-1,826
Closed -$81K 1903
2024
Q1
$81K Sell
1,826
-8,683
-83% -$396K ﹤0.01% 1239
2023
Q4
$484K Buy
10,509
+794
+8% +$33.8K ﹤0.01% 748
2023
Q3
$417K Buy
9,715
+782
+9% +$36.5K ﹤0.01% 753
2023
Q2
$427K Buy
8,933
+4,277
+92% +$206K ﹤0.01% 782
2023
Q1
$227K Buy
4,656
+505
+12% +$25.7K ﹤0.01% 930
2022
Q4
$220K Sell
4,151
-4,374
-51% -$216K ﹤0.01% 943
2022
Q3
$374K Buy
8,525
+1,707
+25% +$84.3K ﹤0.01% 814
2022
Q2
$341K Buy
6,818
+3,587
+111% +$175K ﹤0.01% 836
2022
Q1
$168K Buy
3,231
+949
+42% +$49K ﹤0.01% 1081
2021
Q4
$135K Buy
+2,282
New +$131K ﹤0.01% 1134

Other funds holding QGEN

KBC Group's QGEN Position: Q2 2024 in Review

KBC Group sold out of Qiagen (QGEN) in Q2 2024, closing a stake of 1,826 shares — an estimated $81K sold.

KBC Group first reported a position in QGEN in Q4 2021 and held it in 10 quarters. The position peaked at $484K in Q4 2023. 304 funds tracked by Wall St. Rank hold QGEN as of Q2 2024.

  • KBC Group reported no remaining Qiagen position as of Q2 2024 after selling out during the quarter.
  • KBC Group sold 1,826 Qiagen shares in Q2 2024, an estimated $81K.
  • KBC Group first reported a position in Qiagen in Q4 2021 and held it in 10 quarters.
  • KBC Group's Qiagen position peaked at $484K in Q4 2023.
  • 304 funds tracked by Wall St. Rank held Qiagen as of Q2 2024.

Based on KBC Group's 13F filing for Q2 2024, filed 17 Jul 2024.